JP2016501845A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501845A5
JP2016501845A5 JP2015540806A JP2015540806A JP2016501845A5 JP 2016501845 A5 JP2016501845 A5 JP 2016501845A5 JP 2015540806 A JP2015540806 A JP 2015540806A JP 2015540806 A JP2015540806 A JP 2015540806A JP 2016501845 A5 JP2016501845 A5 JP 2016501845A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
androgen
cdk8
inhibitor inhibits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015540806A
Other languages
English (en)
Japanese (ja)
Other versions
JP6310470B2 (ja
JP2016501845A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/067990 external-priority patent/WO2014071143A1/en
Publication of JP2016501845A publication Critical patent/JP2016501845A/ja
Publication of JP2016501845A5 publication Critical patent/JP2016501845A5/ja
Application granted granted Critical
Publication of JP6310470B2 publication Critical patent/JP6310470B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015540806A 2012-11-01 2013-11-01 前立腺がんを処置するための方法 Expired - Fee Related JP6310470B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261721134P 2012-11-01 2012-11-01
US61/721,134 2012-11-01
PCT/US2013/067990 WO2014071143A1 (en) 2012-11-01 2013-11-01 Method for treating prostate cancer

Publications (3)

Publication Number Publication Date
JP2016501845A JP2016501845A (ja) 2016-01-21
JP2016501845A5 true JP2016501845A5 (https=) 2016-12-22
JP6310470B2 JP6310470B2 (ja) 2018-04-11

Family

ID=49641849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015540806A Expired - Fee Related JP6310470B2 (ja) 2012-11-01 2013-11-01 前立腺がんを処置するための方法

Country Status (6)

Country Link
US (1) US9636342B2 (https=)
EP (1) EP2914266B1 (https=)
JP (1) JP6310470B2 (https=)
KR (1) KR20160014568A (https=)
CA (1) CA2890108C (https=)
WO (1) WO2014071143A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106282378A (zh) * 2016-09-28 2017-01-04 湖北工业大学 一种用于细胞周期依赖性蛋白激酶8基因突变检测的试剂及应用
JP7392954B2 (ja) 2017-09-18 2023-12-06 シーゼット・バイオハブ・エスエフ・リミテッド・ライアビリティ・カンパニー トリプルネガティブ乳癌の治療方法
US12281080B2 (en) 2018-08-21 2025-04-22 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
CN113677341B (zh) * 2019-02-01 2024-07-05 南卡罗莱纳大学 双环吡啶组合物及其用于癌症治疗的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005327921A1 (en) * 2004-11-01 2006-08-31 University Of Southern California Novel compounds for treatment of cancer and disorders associated with angiogenesis function
US8598344B2 (en) * 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
US8987275B2 (en) * 2010-03-16 2015-03-24 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
EA027531B1 (ru) 2011-09-13 2017-08-31 Игорь Ронинсон ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-κB
KR20150023223A (ko) 2012-02-02 2015-03-05 세넥스 바이오테크놀러지 인코포레이티드 Cdk8/cdk19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도

Similar Documents

Publication Publication Date Title
MX2020013649A (es) Composiciones y metodos para inhibir la actividad de la arginasa.
JP2016514165A5 (https=)
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
JP2016501845A5 (https=)
PH12018500899A1 (en) Compositions and methods for inhibiting arginase activity
UA118177C2 (uk) Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
JO3419B1 (ar) مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr
WO2015009856A3 (en) Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
HK1210611A1 (en) Histone demethylase inhibitors
MX381342B (es) Compuestos terapeuticos inhibidores.
MX2016002178A (es) Composiciones y metodos terapeuticos para la regresion acelerada de placa.
MX2021010252A (es) Inhibidores del receptor de glucocorticoides.
PE20200444A1 (es) Terapia de combinacion para cancer de prostata
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
CA2908957C (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
WO2016004404A3 (en) Gls1 inhibitors for treating disease
PH12016502353A1 (en) Pharmaceutical composition
MX2016014436A (es) Derivados de heterociclil-butanamida.
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
WO2013019093A3 (en) Novel aniline derivatives and use thereof